Satellos Bioscience GAAP EPS of -$0.03
Source: SeekingAlpha
2025-11-14 13:47:48 ET
More on Satellos Bioscience Inc.
- Satellos Bioscience: Promising Novel Treatment For Duchenne Muscular Dystrophy
- Seeking Alpha’s Quant Rating on Satellos Bioscience Inc.
- Historical earnings data for Satellos Bioscience Inc.
- Financial information for Satellos Bioscience Inc.
Read the full article on Seeking Alpha
For further details see:
Satellos Bioscience GAAP EPS of -$0.03
Satellos Bioscience Inc.
NASDAQ: MSCLF
MSCLF Trading
84.07% G/L:
$0.9218 Last:
94,964 Volume:
$0.88 Open:
MSCLF Latest News
February 12, 2026 07:00:00 am
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
February 05, 2026 04:20:00 pm
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq
January 29, 2026 07:00:00 am
Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
January 28, 2026 07:00:00 am
Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
MSCLF Stock Data
$14,249,699
13,361,155
0.12%
8
N/A
Biotechnology & Life Sciences
Healthcare
CA
Toronto
